Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Jul 16, 2022 5:19pm
223 Views
Post# 34829337

RE:RE:The issue of the safe use of higher doses of vaccinia virus

RE:RE:The issue of the safe use of higher doses of vaccinia virus The issue of the safe use of higher doses of vaccina virus is described in collaboration announcement of Signa Technologies and Kalivir Immunotherapeutics for Signa's drug TPOXX, which is a powerful antiviral drug to vaccinia. The collaboration's purpose is to work towards achieving the safe use of vaccinia virus (VV) vectors at higher doses and to bring levels of assurance to physicians, regulators, and especially patients receiving this virus since the vaccina virus is the cow smallpox virus that could potentially revert to its infectious wild state at high doses levels.

In seperate news involving CAR-T therapy in combination with oncolytic virus, a  pre-clinical animal study conducted by the Mayo Clinic tested the effects of an oncolytic vesicular stomatitis virus (VSV) and pelareorep alongside CAR-T and found that those mice that received VSV experienced a reduction in the number of circulating CAR-T cells, which was a negative result. Further analysis showed that the type I interferon released upon VSV infection of tumors promoted T-cell death and increased the expression of several inhibitory receptors of the CAR-T cells. 

In contrast, loading the CAR-T cells with pelareorep produced synergistic anti-tumor effects. Of the seven mice treated with the regimen, four were still alive at the end of the study. Only one of the seven mice that got CAR-T therapy alone survived. The researchers observed even better results in mice that received a pelareorep booster shot eight days after the combo therapy. All seven mice in that group lived through the entire study period.

<< Previous
Bullboard Posts
Next >>